1.
J Cardiovasc Transl Res
; 4(2): 177-81, 2011 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21181320
RESUMO
The field of myocardial regeneration utilizing novel cell-based therapies, gene transfer, and growth factors may prove to play an important role in the future management of ischemic heart disease and cardiomyopathy. Phases I and II clinical trials have been published for a variety of biologics utilizing four methods of delivery: systemic infusion, intracoronary infusion, transvenous coronary sinus, and intramyocardial. This review discusses the advantages and disadvantages of the delivery approaches above.